Skip to main content
logo
Labcorp Holdings Inc. (LH)
NYSE: LH · Real-Time Price · USD
259.69
-15.97 (-5.79%)
At close: Oct 28, 2025, 4:00 PM EDT
260.51
+0.82 (0.32%)
After-hours: Oct 28, 2025, 7:50 PM EDT

Labcorp Holdings Revenue by Segment

Period EndingMar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Diagnostics
10.30B10.15B9.91B9.70B9.51B9.41B9.35B9.21B
Diagnostics Growth
8.26%7.82%5.91%5.22%4.19%2.27%-1.97%-7.39%
Drug Development
2.93B2.92B2.85B2.83B2.82B3.51B4.21B4.89B
Drug Development Growth
3.87%-16.80%-32.26%-42.15%-50.00%-38.45%-27.06%-15.94%

Operating Income by Segment

Period EndingMar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Diagnostics
1.62B1.61B1.60B1.60B1.57B1.59B1.62B1.68B
Diagnostics Growth
3.08%0.95%-1.48%-4.68%-12.13%-21.44%-32.72%-38.97%
Drug Development
466.00M459.00M437.20M425.30M422.50M446.50M546.00M647.70M
Drug Development Growth
10.30%2.80%-19.93%-34.34%-44.14%-44.26%-31.60%-20.40%
General Corporate Expenses
-268.70M-268.30M-269.00M-273.20M-382.10M-389.00M-406.80M-396.80M

Operating Expense Breakdown

Period EndingJun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Selling, General, and Administrative
2.29B2.27B2.23B2.17B2.12B2.07B2.12B2.12B
Selling, General, and Administrative Growth
7.74%9.41%5.30%2.18%0.89%-0.65%6.07%5.87%
Impairments
--349.30M--349.30M349.00M285.50M276.50M274.90M296.20M--463.30M----------------
Impairments Growth
--26.33%--27.06%17.83%-38.38%-40.67%---------------------
Amortization
272.00M265.90M256.40M245.20M237.20M226.50M235.70M237.10M
Amortization Growth
14.67%17.40%8.78%3.42%-3.81%-13.38%-9.10%-18.69%
Restructuring and Other
39.90M47.40M46.00M52.90M42.40M46.60M50.20M43.60M-
Restructuring and Other Growth
-5.90%1.72%-8.37%21.33%-17.19%-41.60%-40.10%-45.43%-
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.